Advertisement

Clovis Oncology's cancer drug succeeds in key study

Share This Page
Clovis Oncology Inc said its ovarian cancer drug rucaparib camsylate (Rubraca) slowed disease progression in a late-stage trial involving patients with various gene mutations who had undergone initial therapy.

Clovis Oncology Inc said its ovarian cancer drug rucaparib camsylate (Rubraca) slowed disease progression in a late-stage trial involving patients with various gene mutations who had undergone initial therapy. FDA last December granted rucaparib camsylate accelerated approval in patients whose tumors have a mutation called BRCA, and whose disease had advanced despite two or more rounds of chemotherapy. Based on the findings of the trial announced on Monday, Clovis plans to submit an application within the next 4 months to expand rucaparib camsylate's label. The drug belongs to a closely watched class of new medicines called PARP inhibitors, which block enzymes involved in repairing damaged DNA, thereby helping to kill cancer cells.

Ad Position: 
Bottom Center Aligned
https://www.reuters.com/article/clovis-study-idUSL3N1JG2T6

Advertisement

Related Content

block-views-related-content-block